-
1 month ago | 
ajmc.com | Ajai Chari |Kyle Munz
In recent years, dramatic clinical trial results in multiple myeloma have dominated plenary sessions and news conferences at major cancer meetings.
-
1 month ago | 
ajmc.com | Kyle Munz |Andrew M. Evens
Collaborative efforts between pediatric and adult oncologists are helping shape a bright future for adult and young adult (AYA) patients with Hodgkin and non-Hodgkin lymphoma alike.
-
1 month ago | 
businessandamerica.com | Kyle Munz
US health policy is poised for significant transformation in the years ahead, Antoine Keller, MD, FACC, FACS, a cardiothoracic surgeon at Ochsner Lafayette General Hospital, and founder of HeartSense, told The American Journal of Managed Care®. While shifting legislative agendas will help drive systemwide change, Keller emphasized that clinicians and providers must ultimately define what is truly valuable in health care.
-
1 month ago | 
ajmc.com | Kyle Munz |Antoine Keller
US health policy is poised for significant transformation in the years ahead, Antoine Keller, MD, FACC, FACS, a cardiothoracic surgeon at Ochsner Lafayette General Hospital, and founder of HeartSense, told The American Journal of Managed Care®. While shifting legislative agendas will help drive systemwide change, Keller emphasized that clinicians and providers must ultimately define what is truly valuable in health care.
-
1 month ago | 
ajmc.com | Kyle Munz |Naim Alkhouri
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), are yet to receive FDA approval for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Multiple ongoing trials, however, are demonstrating the great potential for these drugs to influence MASH resolution and benefit those with more severe fibrosis.
-
1 month ago | 
businessandamerica.com | Kyle Munz
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide (Ozempic), are yet to receive FDA approval for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH). Multiple ongoing trials, however, are demonstrating the great potential for these drugs to influence MASH resolution and benefit those with more severe fibrosis.
-
1 month ago | 
ajmc.com | Kyle Munz |Naim Alkhouri
In a previous installment of his interview with The American Journal of Managed Care®, (AJMC®), Naim Alkhouri, MD, FAASLD, DABOM, chief medical officer, chief of transplant hepatology, and director of the Steatotic Liver Program at Arizona Liver Health pointed to one of the primary obstacles impeding progress in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): awareness.
-
1 month ago | 
ajmc.com | Kyle Munz |Antoine Keller
Technological advancements are rapidly transforming the ways cardiovascular care can be delivered. Among those most impactful for Antoine Keller, MD, FACC, FACS, cardiothoracic surgeon at Ochsner Lafayette General Hospital and founder of HeartSense, are the advent of artificial intelligence (AI) and digital auscultation.
-
1 month ago | 
ajmc.com | Kyle Munz |Andrew M. Evens
Last month, Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center, joined The American Journal of Managed Care® (AJMC®) to spread awareness about the particular challenges that impact adolescent and young adult (AYA) patients with forms of Hodgkin and non-Hodgkin lymphoma (NHL). Later on, he discussed the value of expanding clinical knowledge of lymphoma biology, which could inform the management and treatment of lymphoma in AYA populations.
-
1 month ago | 
ajmc.com | Kyle Munz |Ajai Chari
While much attention has been given to the merits and potential of triple and quadruple therapy in multiple myeloma, Ajai Chari, MD, University of California, San Francisco, emphasized how it is not just the number of agents that matters in successful treatments, but how they are used. Dosing intensity, frequency, and real-world feasibility often carry more weight than the theoretical power of a multi-drug regimen.
